Analytical testing is a critical component of every manufacturing program. As a CDMO with an ISO 9001:2015 certification and ICH Q7 Section 19 compliant quality system, we understand that successful biotherapeutic development and manufacturing are supported by comprehensive testing.
CleanCap technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low capping efficiencies (mCAP/ARCA) or high enzyme costs that are associated with traditional capping methods.
Leverage a legacy of trailblazing innovation in mRNA and 7+ years of GMP mRNA manufacturing with TriLink®. Bringing your mRNA vaccine or therapeutic through the clinic introduces new demands for process development, scalability, and quality. TriLink® leverages cGMP manufacturing processes to deliver mRNA drug substances at scale. Increase your probability of success by partnering with a global leader in mRNA development and manufacturing.
The combination of expertise in synthetic organic chemistry and leading knowledge in mRNA enables TriLink to continually respond to customer needs, providing innovative tools and solutions to the market. Our catalog of mRNA products includes genome editing tools, reporters, antigens, gene replacement proteins, and reprogramming mRNAs, available as both catalog and custom products. Read more about our mRNA and long RNA products and services here.
TriLink oligo scientists and production staff have over 150 years of collective experience with oligonucleotide chemistry and methods development. TriLink offers a wide selection of DNA, RNA, modified, and specialty oligonucleotides. Read more about how our decades of experience designing and synthesizing difficult constructs with unparalleled purity and performance make us a trusted partner for your application goals.
To serve the growing global demand for plasmid DNA as a critical raw material, TriLink now offers plasmid manufacturing services designed with mRNA therapeutics in mind. The manufacturing process is engineered to minimize endotoxin and omits the use of RNase during isolation. Supported by TriLink’s revolutionary CleanCap® technology and over 20 years of experience manufacturing modified nucleotides, in-house production of plasmid further optimizes mRNA production and can provide an advantage to fast-track your project timelines.
